ArticlePain and therapy2023
Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study.
Article in Pain and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Interictal burden in migraine: a systematic review of conceptual domains and measurement properties of instruments.The journal of headache and pain · 2026Pooled it
- "The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials".BMC neurology · 2025Pooled it
- Effectiveness of atogepant in migraine with and without medication overuse: Pooled real-world analysis of two independent clinical cohorts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Observational
- Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study.Headache · 2026Observational
- Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire.Journal of patient-reported outcomes · 2025Article
- Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study.The journal of headache and pain · 2025Article
- Real-world use of over-the-counter medications by patients with migraine in Japan: results from the OVERCOME (Japan) 2nd study.The journal of headache and pain · 2025Observational
- Burden of hidden migraine among the Arab general population: a cross-sectional study.The journal of headache and pain · 2025Article
- Prevalence, Treatment, and Unmet Needs of Migraine in the Middle East: A Systematic Review.Pain and therapy · 2025Review
- Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.JAMA neurology · 2024Article
- Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change.Journal of clinical medicine · 2024Review
- Effect of Smoking on the Development of Migraine in Women: Nationwide Cohort Study in South Korea.JMIR public health and surveillance · 2024Article
- Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain.BMC neurology · 2024Article
- CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society.The journal of headache and pain · 2024Article
- Evolving migraine management: Lithuania's telemedicine experience.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis analysis aimed to evaluate demographics, migraine-related disability, symptoms, diagnosis and healthcare consultation, work productivity, and treatment patterns according to headache frequency in adults with migraine in the OVERCOME (ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE) (Spain) study.
methodsData were obtained from an observational, cross-sectional, web-based survey conducted between October 2020-February 2021 in Spain. Eligible participants were adult members of online survey panels living in Spain who were able to read and write Spanish and fulfilled the International Classification of Headache Disorders, third edition (ICHD-3) criteria for migraine or had a self-reported physician diagnosis.
resultsIn total, 10,229 patients comprised the Spanish sample. Only 56.2% of respondents had a confirmed healthcare professional (HCP) diagnosis of migraine, despite almost all meeting modified ICHD-3 criteria. Pain severity, migraine-related disability, and interictal burden increased with increasing number of headache days per month. Migraine impacted on respondents' work productivity, with increases in presenteeism, work productivity loss, and daily activity impairment at higher headache frequencies. Over the past year, 66.2% of all HCP visits were specifically due to migraine, most commonly with a general practitioner or pharmacist. A subgroup of 1277 patients (12.5% of the total survey population) met eligibility criteria for migraine preventive medications, of whom only 36.6% were currently taking a preventive.
conclusionsResults of the OVERCOME (Spain) survey reveal the substantial burden of migraine, which is directly linked to headache frequency. However, most patients experiencing frequent headaches and eligible for migraine preventives are currently not taking them. Findings highlight the importance of addressing unmet needs for people with migraine in Spain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.